These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 19735276

  • 1. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.
    Lafaurie M, Lapalu J, Raffoux E, Breton B, Lacroix C, Socié G, Porcher R, Ribaud P, Touratier S, Molina JM.
    Clin Microbiol Infect; 2010 Aug; 16(8):1191-6. PubMed ID: 19735276
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD, Lyseng-Williamson KA, Scott LJ.
    Drugs; 2009 Aug; 69(3):361-92. PubMed ID: 19275278
    [Abstract] [Full Text] [Related]

  • 5. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE.
    N Engl J Med; 2004 Sep 30; 351(14):1391-402. PubMed ID: 15459300
    [Abstract] [Full Text] [Related]

  • 6. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, Kontoyiannis DP, Hachem RY.
    Leukemia; 2008 Mar 30; 22(3):496-503. PubMed ID: 18094720
    [Abstract] [Full Text] [Related]

  • 7. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
    Ellis M, Frampton C, Joseph J, Alizadeh H, Kristensen J, Hauggaard A, Shammas F.
    J Med Microbiol; 2006 Oct 30; 55(Pt 10):1357-1365. PubMed ID: 17005784
    [Abstract] [Full Text] [Related]

  • 8. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden.
    Naik S, Lundberg J, Kumar R, Sjolin J, Jansen JP.
    Scand J Infect Dis; 2011 Jul 30; 43(6-7):504-14. PubMed ID: 21332286
    [Abstract] [Full Text] [Related]

  • 9. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M, Martino R, Gómez L, Martí JM, Estany C, Sierra J.
    Eur J Haematol; 2004 May 30; 72(5):342-7. PubMed ID: 15059069
    [Abstract] [Full Text] [Related]

  • 10. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
    Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP.
    Pharmacotherapy; 2007 Dec 30; 27(12):1644-50. PubMed ID: 18041885
    [Abstract] [Full Text] [Related]

  • 11. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
    Yilmaz D, Balkan C, Ay Y, Akin M, Karapinar B, Kavakli K.
    Mycoses; 2011 May 30; 54(3):234-42. PubMed ID: 19906090
    [Abstract] [Full Text] [Related]

  • 12. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin.
    Martino R, Viscoli C.
    Br J Haematol; 2006 Jan 30; 132(2):138-54. PubMed ID: 16398648
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).
    Caillot D, Thiébaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, Larché J, Monchecourt F, Alfandari S, Mahi L.
    Cancer; 2007 Dec 15; 110(12):2740-6. PubMed ID: 17941026
    [Abstract] [Full Text] [Related]

  • 17. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
    Madureira A, Bergeron A, Lacroix C, Robin M, Rocha V, de Latour RP, Ferry C, Devergie A, Lapalu J, Gluckmana E, Socié G, Ghannoum M, Ribaud P.
    Int J Antimicrob Agents; 2007 Dec 15; 30(6):551-4. PubMed ID: 18029149
    [Abstract] [Full Text] [Related]

  • 18. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS.
    N Engl J Med; 1999 Mar 11; 340(10):764-71. PubMed ID: 10072411
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
    Ament AJ, Hübben MW, Verweij PE, de Groot R, Warris A, Donnelly JP, van 't Wout J, Severens JL.
    J Antimicrob Chemother; 2007 Aug 11; 60(2):385-93. PubMed ID: 17561501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.